8. 1. Market Overview
Sales trend
PREGABALIN – by value
2,500,000
2,000,000
1,500,000
1,000,000
500,000
0
Units
Y/2008
(Absolute)
LYRICA
1/31/2013
PREGDIN-APEX
Units
Y/2009
(Absolute)
PREGAVALEX
Units
Y/2010
(Absolute)
IRENYPATHIC
PAINICA
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
Units
Y/2011
(Absolute)
LYROLIN
Units
Y/2012
(Absolute)
KEMIRICA
HEXAGABALIN
8
9. 1. Market Overview
Sales trend
PREGABALIN – by value
2,500,000
2,000,000
This is about 40%
market growth with
indicate special market
situation we need to
dig more about it
1,500,000
1,000,000
500,000
0
Units
Y/2008
(Absolute)
LYRICA
1/31/2013
PREGDIN-APEX
Units
Y/2009
(Absolute)
PREGAVALEX
Units
Y/2010
(Absolute)
IRENYPATHIC
PAINICA
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
Units
Y/2011
(Absolute)
LYROLIN
Units
Y/2012
(Absolute)
KEMIRICA
HEXAGABALIN
9
19. SWOT analysis
1.
2.
Non Competitive Price
3.
Brand Establishment
4.
W
Strength Availability
Low Prescription Rate
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
19
20. SWOT analysis
1.
Highly growing market
2.
Current perception about Pregabalin and
its market growth over other molecules
3.
Shifty from Gebapentin to Pregabalin
4.
Diversify specialty
O
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
20
21. SWOT analysis
1.
Well established competitors
2.
Multiple competitor
3.
Smaller packs and less prices
T
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
21
23. Market Key Issues & Strategic Imperatives
Below the main market key issues and strategies:
1.
2.
3.
4.
5.
1/31/2013
Establish efficacy & credibility
Capitalize on having a unique and un-comparable brand
Generation and growth of prescriptions in several indications
Shape the market of Pregabalin.
Being the first option generic brand in Pregablin market
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
23
25. Pricing
There are four main strategies regarding pricing :
Competitive pricing
Skimming pricing
1/31/2013
Differentiation pricing
Penetration pricing
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
25
26. Pricing
There are four main strategies regarding pricing :
Competitive pricing
Skimming pricing
1/31/2013
Differentiation pricing
Penetration pricing
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
26
27. Pricing
How can we compare prices with different concentration & number of tablets ??!!
We can use this Equation
Prices Index =
Price per tablet (Price / no. tablet )
X 100
Concentration
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
27
29. Pricing
From the price index before we can find that:
1.
HEXGABALIN is an average generic brand price.
2.
According to the market leader we are about 40% more economic that Lyrica
3.
According to PREGDIN-APEX (18% total market share ) we are slightly more expensive
4.
We do not have enough high concentrations, low value concentrations
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
29
30. 6. Source of business
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
30
32. Indication %
Indication %
Others
8%
POLYNE/OTH DIS PERIP
5%
VIR INF SK/M MEM LES
6%
DIABETES MELLITUS
28%
NER/NER RT/PLEX DIS
8%
OTH SOFT TISSUE DIS
8%
OTHER DORSOPATHIES
SPONDYLOPATHIES
OTH SOFT TISSUE DIS
NER/NER RT/PLEX DIS
VIR INF SK/M MEM LES
POLYNE/OTH DIS PERIP
SPONDYLOPATHIES OTHER DORSOPATHIES
10%
27%
1/31/2013
DIABETES MELLITUS
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
Others
32
33. Source of business
Based on
RXs
We need to focus on below specialty:
1.
Ortho
2.
GPs
3.
Neuro
4.
IM
We need to focus on these indications:
2.
OTHER DORSOPATHIES
3.
SPONDYLOPATHIES
OTHER SOFT TISSUE DIS
5.
1/31/2013
DIABETES MELLITUS
4.
and indication
1.
NER/NER RT/PLEX DIS
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
33
35. Vision
To be the generic of choice for neuropathic pain
Build a great credibility approach among doctors
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
35
36. Mission
For re-launching HEXGABALIN we need different missions and strategies to build our brand
between this big market full of competitors
S
Build the
perception
1/31/2013
S2
Hitting the
competitors
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
S3
Fulfilling
the market
gaps
36
37. Positioning
In this busy market we need to take different approach to enter a market we do
not have a tangible differentiation points, we all had the same molecule and the
same average prices
We need to select and focus on powerful positioning strategy to
enter this market the right way
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
37
39. Positioning strategies
1st phase (two Q)
We will use this strategy to enter the market in different way to build a powerful perception and
create a good positioning
It is not for sales generation as we will target the unexpected market just for branding
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
39
40. Positioning strategies
2nd phase (two Q)
We will use this strategy to enter the market in different ways to build a powerful perception
and create a good positioning
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
40
42. Strategy
We will create a universal campaign for neuro specialty, using the same message and materials
for all specialties, then start customizing it for each indication.
1st phase
We will focus on neuro as an
anti-epileptic product
2nd phase
Hitting the competitors in
their main indication,
• in Diabetic nephropathy
• Ortho
1/31/2013
3rd phase
General neuropathic pain
product of choice, with
customized materials for
each indication
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
42
43. Strategy
We will create a universal campaign for neuro specialty, using the same message and materials
for all specialties, then start customizing it for each indication.
Gratefully our
honorable
st phase
1
competitors
already did this
We will focus on neuro as an
anti-epileptic product
step for us
regarding
awareness of
pregablin and
neuro molecule in
neuropathic cases
1/31/2013
2nd phase
Hitting the competitors in
their main indication,
• in Diabetic nephropathy
• Ortho
3rd phase
General neuropathic pain
product of choice, with
customized materials for
each indication
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
43
44. Creative
Idea
Generation
1/31/2013
To enter this busy market we need to
catch/different/reminding message.
Differentiate our product from the competitor’s
Address important customer buying criteria
Highlight key product characteristics
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
44
48. THE
HEXA
HEXGABALIN
The HEXA reasons why you need to use Hexgabalin
The HEXA advantages of Hexgabalin
The HEXA indications of Hexgabalin
Etc..
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
48
51. Sales trend
Estimated 2013 sales
300,000,000
251,517,942
250,000,000
193,475,340
200,000,000
149,329,761
150,000,000
113,145,175
100,000,000
214,300,281
153,071,629
105,627,381
71,940,784
40,459,490
32,249,497
41,204,391
43,702,380
40,403,711
36,363,340
LE Sales
Y/2008
(Absolute)
50,000,000
51,729,996
29,594,234
22,135,762
72,708,987
LE Sales
Y/2009
(Absolute)
LE Sales
Y/2010
(Absolute)
LE Sales
Y/2011
(Absolute)
LE Sales
Y/2012
(Absolute)
LE Sales
Y/2013
(Estimated)
-
PREGABALIN
1/31/2013
GABAPENTIN
Total market
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
51
52. Sales Forecasting - value
We will forecast about 3% total market share for year 2013:
Total market 2013 = 250M LE
||
Hexgablin = 250M x 3% = 7.5M LE
That means 500% growth over last year
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
52
54. Sales Forecasting - unit
√ The sales of 75mg caps overcomes 150mg by almost double share
√ The 50mg overtake the 75mg in some brands
√ Unsuccessful 300mg concentrations due to unknown reasons (needs field
research)
√ The smaller the pack, the larger the reach
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
54
55. Forecaster 2013
Description
Price/RS Price/P
P
TT
Unit
HEXAGABALIN
Feb
Mar
Qtr. I
Apr
May
Jun
Qtr. II
Jul
Aug
Sep
Qtr. III
Oct
Nov
Dec
Qtr. IV
Total
2013
2013
2013
2013
2013
2013
2013
2013
2013
2013
2013
2013
2013
2013
2013
2013
unite
33%
Unit
Jan
33%
33%
12%
33%
33%
33%
12%
39%
37%
24%
41%
43%
29%
29%
35%
CAPS 75 MG 30
EGP
120.00 84.00
2,400
2,400
2,400
7,200
2,400
2,400
2,400
7,200
9,577
8,978
5,986
24,541
9,000
6,000
6,000
21,000
60,000
CAPS 150 MG 30
EGP
111.00 77.70
1,120
1,120
1,120
3,360
1,120
1,120
1,120
3,360
4,469
4,190
2,793
11,452
4,200
2,800
2,800
9,800
28,000
3,520
3,520
3,520
10,560
3,520
3,520
3,520
10,560
14,046
13,168
8,779
35,993
13,200
8,800
8,800
30,800
88,000
Total . Sales (units)
TotalT. Turnover (LE)
1/31/2013
288,624 288,624 288,624 865,872 288,624 288,624 288,624 865,872
1,151,72 1,079,74
1,082,34
719,826 2,951,288
721,560 721,560 2,525,460 7,215,600
2
0
0
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
55
56. 10. The A&P budget
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
56
57. A&P budget
We had four main methods to estimate our target
Fixed
percentage
of sales
1/31/2013
Same level
as
competitors
Task
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
Residual
57
58. A&P budget
Same level
as
competitors
1/31/2013
Due to market potentiality and our
positioning strategy we need to invest in our
brand till building our perception, then we
can take % from sales to update our
activities
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
58
60. Sales force Structure
To calculate sales force structure we need to
calculate number of doctors with their
potentiality in each governor
Based on our phasing criteria we will select
the right specialty.
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
60
61. Sales force Structure
We will use the below equation to calculate each area potentiality, therefore number of medical
reps will cover it
SEC
class
# of
Visits/
doctors month
A
8
B
4
C
2
x 11 month
# medical reps =
# medical reps visits per year
1/31/2013
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
61
63. Key Innovative Projects.
To create a tipping point in our brand we need to make adramatic change in the market
characteristic to gain a noticeable market share
The
Concentration
VS packing
1/31/2013
The HEXA
indication
project
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
Chronic user
trade deal
63
65. Calendar of activities.
Item
New Launches
2012
January
February
March
April
May
June
Facelifting Gel
New aftershave bottle
July
August
Shaving cream
aftershave cologne
September October
November
December Total
-
Promotion
Key Account
Buy two get one offer
Nothing else campaign
150+Blam offer
Instore activ
35,000
35,000
gel+balm
Wholesaler
BiC Bundle
Nothing else campaign
20,000 Covarage*
gel+balm
20,000
Retail
BiC Bundle
Nothing else campaign
10,000
gel+balm
10,000
El-Koshk
Communication
BiC Bundle
-
TV
-
Radio
120,000
280,000
160,000
Magazine
30,000
30,000
OutDoors
700,000
700,000
80,000
200,000
-
Online
Road Show
120,000
102,000
Summer
Total Budget
1/31/2013
-
-
-
-
240,000
-
102,000
50,000
Cairo
50,000
312,000
840,000
HEXAGABLIN RE-LAUNCH PLAN - ABDELRHMAN TANTAWY
35,000
-
-
-
1,427,000
65